The WBP11 antibody is validated for multiple experimental techniques:
| Application | Dilution | Notes |
|---|---|---|
| WB | 1:1,000–1:6,000 | Optimal signal achieved at 1:1,500 in HeLa lysates |
| IP | 0.5–4.0 µg per 1–3 mg lysate | Requires overnight incubation at 4°C |
| IHC | 1:50–1:500 | TE buffer pH 9.0 recommended for antigen retrieval |
The WBP11 antibody has been instrumental in studying the role of WBP11 in human congenital malformations. A 2020 study linked heterozygous loss-of-function (LoF) mutations in the WBP11 gene to a pleiotropic syndrome affecting cardiac, skeletal, gastrointestinal, and renal systems . Key findings include:
Haploinsufficiency: Reduced WBP11 expression (0.53× of wild-type levels) in heterozygous mouse embryos caused axial skeletal defects and organ hypoplasia .
Splicing Defects: WBP11 antibodies confirmed disrupted splicing machinery in patient-derived cells, correlating with phenotypic severity .
| Method | Key Steps |
|---|---|
| WB Protocol | 1. Lyse cells in RIPA buffer; 2. Resolve proteins on 4–12% Bis-Tris gel; 3. Probe with WBP11 antibody at 1:1,500 overnight |
| IHC Protocol | 1. Fix paraffin sections; 2. Retrieve antigens with TE buffer pH 9.0; 3. Block with 5% BSA; 4. Incubate with antibody at 1:100 overnight |
KEGG: dre:110437720
UniGene: Dr.78113